Skip to Main Content

Paper Details

Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
Journal of Clinical Investigation
46
2018
ATCs, Anaplastic thyroid carcinomas, BRAF, BRAFV600E, CH5126766, HGF, Hgf, MAPK, MEK, MET, Met, Met kinase, Met-, Met-amplified tumor cells, Met-diploid relapses, PF-04217903, RAF, TP53, TP53 mutations, amplified recurrences, anaplastic thyroid cancers, chromosome 6, crizotinib, dox, mice, murine, nonmelanoma BRAFV600E-mutant cancers, p53, relapsed tumors, tumors, vemurafenib

Datasets

Release 1.2